Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

(1) Feinberg School of Medicine, Northwestern University,Chicago,United States

(2) Icahn School of Medicine at Mount Sinai,New York City,United States

(3) Robarts Clinical Trials Inc.,London,Canada

(4) Janssen Biologics BV,Leiden,Netherlands

(5) AMARIS,Toronto,Canada

(6) Janssen Scientific Affairs, LLC,Horsham,United States

(7) Janssen Research & Development, LLC,Spring House,United States

(8) Janssen Research & Development, LLC,Horsham,United States

(9) Janssen,Horsham,United States

(10) Cedars-Sinai Med Ctr,Los Angeles,United States

(11) Stellenbosch University,Stellenbosch,South Africa

(12) University Hospitals, Leuven,Leuven,Belgium

(13) Institute of Translational Medicine,Birmingham,United Kingdom

This item was part of the Holistic management of IBD patients session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

You may be interested in:

Takeda - Histologic remission in ulcerative colitis: Are we ready? Insights from VARSITY (Takeda Pharmaceuticals International AG)
English, Presentation, Industry Sponsored Symposia, Takeda Pharmaceuticals International AG, Industry Sponsored Symposia, 2019


  • Format
    • Abstract
  • Year
    • 2019